Using the SARS-CoV-2 tests , explain the processes required for scaling up production of the newer diagnostic testing in a global pandemic and regulatory processes required for use of new diagnostic tests for COVID-19 within Australia, Europe and the United States of America.
Ans) Infection with the virus causing COVID-19 (SARS-CoV-2) is confirmed by the presence of viral RNA detected by molecular testing, usually RT-PCR.
- Detection of viral RNA does not necessarily mean that a person is infectious and able to transmit the virus to another person.
- Factors that determine transmission risk include whether a virus is still replication-competent, whether the patient has symptoms, such as a cough, which can spread infectious droplets, and the behavior and environmental factors associated with the infected individual.
- 5-10 days after infection with SARS-CoV-2, the infected individual starts to gradually produce neutralizing antibodies. Binding of these neutralizing antibodies to the virus is expected to reduce the risk of virus transmission.
Get Answers For Free
Most questions answered within 1 hours.